Jump Financial’s Myriad Genetics MYGN Stock Holding History

Jump Financial’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.03M	Buy	+181,010	New	+$822K	0.01%	1175
2026 Q1	–	Sell	-168,597	Closed	-$1.04M	–	2222
2025 Q4	$1.04M	Buy	168,597 +6,989	+4%	+$50.7K	0.01%	958
2025 Q3	$1.17M	Buy	161,608 +151,017	+1,426%	+$897K	0.01%	951
2025 Q2	$56.2K	Sell	10,591 -123,745	-92%	-$731K	﹤0.01%	1691
2025 Q1	$1.19M	Buy	+134,336	New	+$1.61M	0.02%	758
2024 Q4	–	Sell	-32,857	Closed	-$900K	–	1874
2024 Q3	$900K	Buy	+32,857	New	+$889K	0.02%	842
2024 Q1	–	Sell	-19,047	Closed	-$365K	–	2153
2023 Q4	$365K	Sell	19,047 -65,877	-78%	-$1.14M	0.01%	1228
2023 Q3	$1.36M	Buy	84,924 +11,706	+16%	+$223K	0.05%	526
2023 Q2	$1.7M	Buy	+73,218	New	+$1.6M	0.06%	453
2023 Q1	–	Sell	-46,029	Closed	-$668K	–	1891
2022 Q4	$668K	Buy	+46,029	New	+$858K	0.04%	662

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jump Financial's MYGN Position: Q2 2026 in Review

Jump Financial opened a new position in Myriad Genetics (MYGN) in Q2 2026: 181,010 shares worth $1.03M. The stake represents 0.01% of the portfolio and ranks #1175 among its holdings. This is a return to the name: Jump Financial previously reported a position in MYGN as recently as Q4 2025.

Jump Financial first reported a position in MYGN in Q4 2022 and has held it in 10 quarters since. The position peaked at $1.7M in Q2 2023. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Jump Financial held 181,010 shares of Myriad Genetics worth $1.03M as of Q2 2026.
Myriad Genetics was a new Jump Financial position in Q2 2026.
Myriad Genetics made up 0.01% of Jump Financial's portfolio in Q2 2026, its #1175 holding.
Jump Financial first reported a position in Myriad Genetics in Q4 2022 and has held it in 10 quarters since.
Jump Financial's Myriad Genetics position peaked at $1.7M in Q2 2023.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.